Tirzepatide for Alcohol Use Disorder
NCT06994338
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alcohol Use Disorder
- Obesity and Overweight
- Alcohol
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 21 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of Southern California
- Last updated on ClinicalTrials.gov
- October 14, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Keck School of Medicine, University of Southern California · Los Angeles, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.